21Jun/13

Novartis heart failure drug gets FDA incentives – Bioscience Technology


Economic Times

Novartis heart failure drug gets FDA incentives
Bioscience Technology
Novartis said patients treated with serelaxin in a late-stage trial were 37 percent less likely to die in the six months after a heart failure episode compared with patients who received standard treatment. The FDA created the breakthrough therapy
FDA grants Breakthrough Therapy designation to Novartis’ serelaxin (RLX030 FierceBiotech
US FDA deems Novartis’ heart failure candidate a ‘breakthrough’PMLiVE
Novartis Heart-Failure Drug Wins ‘Breakthrough’ Status at FDABusinessweek
Medical Daily –DailyFinance –TheHeart.Org
all 13 news articles »